Actively Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Led by MOMA Therapeutics · Updated on 2026-04-15
132
Participants Needed
14
Research Sites
145 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
CONDITIONS
Official Title
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Unresectable advanced or metastatic solid tumors with MSI-H or dMMR confirmed by tissue analysis
- Must have progressed after anti-PD-(L)1 therapy unless ineligible or without access to such treatments
- Have at least one lesion measurable or suitable for imaging evaluation
- ECOG performance status of 2 or less
- Fully recovered from prior therapy effects; hormonal and palliative radiotherapy allowed
- Adequate organ function based on local laboratory tests
- Must follow contraception requirements
- Provide written informed consent according to local rules
You will not qualify if you...
- Known Werner Syndrome
- Active prior or concurrent advanced-stage cancers (some early-stage cancers allowed)
- Clinically relevant heart or cardiovascular disease
- Known brain metastases with worsening neurological symptoms (stable corticosteroid doses allowed)
- Active uncontrolled infections
- Allergy, hypersensitivity, or intolerance to MOMA-341
- Impaired gastrointestinal function affecting drug absorption
- Pregnancy or breastfeeding
- HIV positive unless viral load is undetectable, CD4+ count at least 300 cells/µL, on therapy, and no AIDS illness in past year
- Active liver disease (some exceptions apply)
- Any condition or therapy that may affect patient safety, study results, or participation as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Investigative Site #101
San Diego, California, United States, 92037
Actively Recruiting
2
Investigative Site #128
Tampa, Florida, United States, 33612
Actively Recruiting
3
Investigative Site #120
Detroit, Michigan, United States, 48201
Actively Recruiting
4
Investigative Site #110
St Louis, Missouri, United States, 63108
Actively Recruiting
5
Investigative Site #131
Raleigh, North Carolina, United States, 27710
Actively Recruiting
6
Investigative Site #121
Portland, Oregon, United States, 97239
Actively Recruiting
7
Investigative Site #127
Dallas, Texas, United States, 75230
Actively Recruiting
8
Investigative Site #129
Houston, Texas, United States, 77030
Actively Recruiting
9
Investigative Site #122
Sydney, New South Wales, Australia, 2031
Actively Recruiting
10
Investigative Site #123
Westmead, New South Wales, Australia, 2145
Actively Recruiting
11
Investigative Site #124
Woolloongabba, Queensland, Australia, 4102
Actively Recruiting
12
Investigative Site #125
Adelaide, South Australia, Australia, 5000
Actively Recruiting
13
Investigative Site #126
Clayton, Victoria, Australia, 3168
Actively Recruiting
14
Investigative Site #119
Perth, Western Australia, Australia, 6009
Actively Recruiting
Research Team
M
MOMA Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here